Revolution Medicines (RVMD) Common Equity (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Common Equity of $1.5 billion for Q1 2026, down 27.82% year-over-year from $2.1 billion in Q1 2025, and down 8.05% quarter-over-quarter from $1.6 billion in Q4 2025.
Revolution Medicines (RVMD) Common Equity (2019 - 2026) Analysis & Trends
Revolution Medicines' Common Equity history runs 8 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- In Q1 2026, Common Equity fell 27.82% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (down 27.82% YoY), while the FY2025 annual figure was $1.6 billion, down 27.98% from the prior year.
- Common Equity for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
- The five-year high for Common Equity was $2.3 billion in Q4 2024, with the low at $498.8 million in Q2 2022.
- The 5-year median for Common Equity is $1.6 billion (2024), against an average of $1.3 billion.
- The sharpest annual moves came in 2023 and 2025: Common Equity surged 166.52% in 2023, then decreased 27.98% in 2025.
- Revolution Medicines' Common Equity stood at $685.2 million in 2022, then soared by 166.52% to $1.8 billion in 2023, then increased by 24.04% to $2.3 billion in 2024, then fell by 27.98% to $1.6 billion in 2025, then slipped by 8.05% to $1.5 billion in 2026.
- Business Quant data shows RVMD's Common Equity at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.61 Bn |
| Mar 31, 2026 | 1.50 Bn |
| Dec 31, 2025 | 1.63 Bn |
| Sep 30, 2025 | 1.60 Bn |
| Jun 30, 2025 | 1.87 Bn |
| Mar 31, 2025 | 2.08 Bn |
| Dec 31, 2024 | 2.27 Bn |
| Sep 30, 2024 | 1.57 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | 1.73 Bn |
| Dec 31, 2023 | 1.83 Bn |
| Sep 30, 2023 | 837.46 Mn |
| Jun 30, 2023 | 930.84 Mn |
| Mar 31, 2023 | 952.22 Mn |
| Dec 31, 2022 | 685.19 Mn |
| Sep 30, 2022 | 681.42 Mn |
| Jun 30, 2022 | 498.84 Mn |
| Mar 31, 2022 | 550.99 Mn |
| Dec 31, 2021 | 602.57 Mn |
| Sep 30, 2021 | 638.20 Mn |